It can be argued that for example phosphorylated PTEN should also be included, even though this mediator may be less important in AML than in many other malignancies at least with regard to PTEN mutations; PTEN seems to be mutated in less than 1% of AML patients. This evidence concerns the gene PTEN and acute myeloid leukemia.